Literature DB >> 12176807

Living with rheumatoid arthritis: expenditures, health status, and social impact on patients.

H M Lapsley1, L M March, K L Tribe, M J Cross, B G Courtenay, P M Brooks.   

Abstract

OBJECTIVE: To determine costs related to living with rheumatoid arthritis (RA), and to identify the association between health status-as measured by the Health Status Questionnaire short form-36 (SF-36) and the disease specific index Health Assessment Questionnaire (HAQ)-and the social impact of RA.
METHODS: A prospective cohort study was carried out on 81 patients with RA who completed four consecutive three month cost diaries. The SF-36, HAQ, and social impact at baseline and one year follow up were also assessed.
RESULTS: Women reported worse SF-36 physical function and HAQ scores than men and received more assistance from family and friends. Women spent more on non-prescription medication and devices to assist them than men. Older patients had higher expenditure on visits to health professionals, whereas younger patients spent more on prescription medication and tests. Pension status and membership of private health insurance schemes were important determinants in these differences in expenditure.
CONCLUSION: Costs increased with duration of disease, those with private health insurance had greater out of pocket costs (excluding membership fees), and those with pension support had fewer costs. Women were more affected by RA than men in health status, social impact, and out of pocket costs.

Entities:  

Mesh:

Year:  2002        PMID: 12176807      PMCID: PMC1754210          DOI: 10.1136/ard.61.9.818

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  26 in total

1.  Quality of life in Indian patients with rheumatoid arthritis.

Authors:  Gurdesh S Bedi; Nikhil Gupta; Rohini Handa; Hemraj Pal; R M Pandey
Journal:  Qual Life Res       Date:  2005-10       Impact factor: 4.147

2.  Cost-effective analysis of disease-modifying anti-rheumatic drugs in rheumatoid arthritis.

Authors:  Ashit Syngle; Sudeep Kaur; Inderjeet Verma; Tanya Syngle; Vijaita Syngle
Journal:  Clin Rheumatol       Date:  2017-06-21       Impact factor: 2.980

Review 3.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  Changes in priorities for improvement in patients with rheumatoid arthritis during 1 year of anti-tumour necrosis factor treatment.

Authors:  Peter M ten Klooster; Martine M Veehof; Erik Taal; Piet L C M van Riel; Mart A F J van de Laar
Journal:  Ann Rheum Dis       Date:  2007-05-01       Impact factor: 19.103

5.  Health-related quality of life in Moroccan patients with rheumatoid arthritis.

Authors:  Yousra Ibn Yacoub; Bouchra Amine; Assia Laatiris; Najia Hajjaj-Hassouni
Journal:  Clin Rheumatol       Date:  2012-08-18       Impact factor: 2.980

6.  Costs of ankylosing spondylitis in three European countries: the patient's perspective.

Authors:  A Boonen; D van der Heijde; R Landewé; F Guillemin; A Spoorenberg; H Schouten; M Rutten-van Mölken; M Dougados; H Mielants; K de Vlam; H van der Tempel; Sj van der Linden
Journal:  Ann Rheum Dis       Date:  2003-08       Impact factor: 19.103

7.  Burden and cost of illness in patients with juvenile idiopathic arthritis.

Authors:  K Minden; M Niewerth; J Listing; T Biedermann; M Schöntube; A Zink
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

Review 8.  Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis.

Authors:  Katherine A Lyseng-Williamson; Rachel H Foster
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

9.  Health-related quality of life in rheumatoid arthritis in Northern Sweden: a comparison between patients with early RA, patients with medium-term disease and controls, using SF-36.

Authors:  Elisabet West; Solveig Wållberg Jonsson
Journal:  Clin Rheumatol       Date:  2004-08-31       Impact factor: 2.980

Review 10.  Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?

Authors:  Sergio Schwartzman; Roy Fleischmann; G James Morgan
Journal:  Arthritis Res Ther       Date:  2004-06-21       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.